Breadcrumb

[A16-33] Mepolizumab - Addendum to Commission A16-03

Overview

Overview

Commission: Commission awarded on 2016-06-06 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to Commission A16-03  [PDF, 282 kB]Further documents
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A16-03] Mepolizumab - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2016-07-28 Addendum to Commission A16-03 282 kBPDFdownload file

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


At a glance

Accompanying information

Health information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Mepolizumab (Nucala) for the treatment of severe asthma

Federal Joint Committee (G-BA)

2016-07-21 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close